$0.32
+0.00 (+0.37%)
Open$0.32
Previous Close$0.32
Day High$0.33
Day Low$0.32
52W High$1.70
52W Low$0.28
Volume—
Avg Volume91.9K
Market Cap7.36M
P/E Ratio—
EPS$-1.27
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+12,607.7% upside
Current
$0.32
$0.32
Target
$40.83
$40.83
$24.77
$40.83 avg
$47.84
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 731.6K | 1.39M | 2.02M |
| Net Income | -50,659,034 | -86,662,479 | 234.8K |
| Profit Margin | -6,925.2% | -6,578.9% | 11.6% |
| EBITDA | -56,050,956 | -101,213,473 | 368.8K |
| Free Cash Flow | — | — | 168.2K |
| Rev Growth | -47.4% | -47.4% | +14.4% |
| Debt/Equity | 0.33 | 0.33 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |